Blueprint Medicines Corp
NASDAQ:BPMC

Watchlist Manager
Blueprint Medicines Corp Logo
Blueprint Medicines Corp
NASDAQ:BPMC
Watchlist
Price: 90.33 USD 0.21% Market Closed
Market Cap: 5.7B USD
Have any thoughts about
Blueprint Medicines Corp?
Write Note

Blueprint Medicines Corp
Cash from Financing Activities

Last Value
3-Years 3-Y CAGR
5-Years 5-Y CAGR
10-Years 10-Y CAGR
Quarterly
Annual
TTM
|

Blueprint Medicines Corp
Cash from Financing Activities Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Cash from Financing Activities CAGR 3Y CAGR 5Y CAGR 10Y
Blueprint Medicines Corp
NASDAQ:BPMC
Cash from Financing Activities
$358.9m
CAGR 3-Years
12%
CAGR 5-Years
1%
CAGR 10-Years
N/A
Abbvie Inc
NYSE:ABBV
Cash from Financing Activities
-$2.8B
CAGR 3-Years
45%
CAGR 5-Years
25%
CAGR 10-Years
1%
Gilead Sciences Inc
NASDAQ:GILD
Cash from Financing Activities
-$6.8B
CAGR 3-Years
0%
CAGR 5-Years
4%
CAGR 10-Years
-3%
Amgen Inc
NASDAQ:AMGN
Cash from Financing Activities
-$5.3B
CAGR 3-Years
0%
CAGR 5-Years
21%
CAGR 10-Years
N/A
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
Cash from Financing Activities
-$1.2B
CAGR 3-Years
1%
CAGR 5-Years
-55%
CAGR 10-Years
N/A
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
Cash from Financing Activities
-$1.5B
CAGR 3-Years
-55%
CAGR 5-Years
N/A
CAGR 10-Years
N/A
No Stocks Found

Blueprint Medicines Corp
Glance View

Market Cap
5.7B USD
Industry
Biotechnology
Economic Moat
Narrow

In the demanding world of biotechnology, Blueprint Medicines Corp stands out as an influential player, steering the course of precision therapy through innovation. Founded by a team of forward-thinking scientists, the company is deeply entrenched in the pursuit of novel treatments targeting rare genetic diseases and cancers driven by specific genomic alterations. Leveraging its proprietary compound library and a research-centric approach, Blueprint Medicines develops small-molecule kinase inhibitors designed to selectively modulate growth and survival signals in cells. The company’s strategic focus on genomically defined indications allows it to address unmet medical needs, thereby creating substantial value through focused research and rapid clinical advancements. The financial backbone of Blueprint Medicines is built upon a well-rounded strategy encompassing both in-house drug development and strategic collaborations. As the company shepherds its proprietary drugs through the rigorous phases of clinical trials, it also engages in valuable partnerships with pharmaceutical giants to bolster its research capabilities and market reach. With approval and commercialization of therapies like Ayvakit for certain forms of gastrointestinal stromal tumors, Blueprint Medicines generates substantial revenue. These gains are further compounded by milestone payments and royalties from collaborations, all while maintaining a robust pipeline to ensure continued innovation and future income streams. In this way, Blueprint marries scientific rigor with strategic acumen, carving out a sustainable and impactful presence in the biopharmaceutical landscape.

BPMC Intrinsic Value
105.02 USD
Undervaluation 14%
Intrinsic Value
Price

See Also

What is Blueprint Medicines Corp's Cash from Financing Activities?
Cash from Financing Activities
358.9m USD

Based on the financial report for Sep 30, 2024, Blueprint Medicines Corp's Cash from Financing Activities amounts to 358.9m USD.

What is Blueprint Medicines Corp's Cash from Financing Activities growth rate?
Cash from Financing Activities CAGR 5Y
1%

Over the last year, the Cash from Financing Activities growth was 238%. The average annual Cash from Financing Activities growth rates for Blueprint Medicines Corp have been 12% over the past three years , 1% over the past five years .

Back to Top